- Bluebird Bio (NASDAQ:BLUE) initiated with Buy rating and $202 (25% upside) price target by Canaccord Genuity.
- Audentes Therapeutics (NASDAQ:BOLD) initiated with Outperform rating and $35 (26% upside) price target by BMO.
- BeyondSpring (NASDAQ:BYSI) initiated with Buy rating and $56 (70% upside) price target by Seaport Global.
- Erytech Pharma (Pending:ERYP) initiated with Outperform rating by Cowen & Co.
- Repligen (NASDAQ:RGEN) initiated with Overweight rating and $42 (24% upside) price target by JPMorgan (NYSE:JPM).
- Neogen (NASDAQ:NEOG) resumed with Neutral rating and $82 (2% downside risk) price target by Roth Capital.
- Depomed (NASDAQ:DEPO) upgraded to Buy with a $9 (29% upside) price target by Mizuho.
- Sunesis Pharmaceuticals (NASDAQ:SNSS) downgraded to Market Perform with a $2 (26% downside risk) price target by Wells Fargo (NYSE:WFC).
- Source: Bloomberg
- Now read: bluebird bio Achieves Favorable Interim Data In Fatal Brain Disease In Children
Original article